THNR
Amplify ETF Trust - Amplify Weight Loss Drug & Treatment ETF

27
Loading...
Loading...
News
all
press releases
News Placeholder
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.
Zacks·1mo ago
News Placeholder
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Zacks·4mo ago

Latest THNR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.